Compounds > 5-bromo-5-nitro-1,3-dioxane
Page last updated: 2024-09-20

5-bromo-5-nitro-1,3-dioxane

Description

5-bromo-5-nitro-1,3-dioxane: structure in first source [Medical Subject Headings (MeSH), National Library of Medicine, extracted Dec-2023]

Cross-References

ID SourceID
PubMed CID1807
CHEMBL ID3185787
SCHEMBL ID97282
SCHEMBL ID17347337
MeSH IDM0546458

Synonyms (41)

Synonym
AKOS015834980
5-bromo-5-nitro-1,3-dioxane
1,3-dioxane, 5-bromo-5-nitro-
5-brom-5-nitro-1,3-dioxan [german]
m-dioxane, 5-bromo-5-nitro-
brn 4668673
5-bromo-5-nitro-m-dioxane
einecs 250-001-7
bronidox
5-bromo-5-nitro-1,3-dioxane, >=99%
B3156
30007-47-7
NCGC00255969-01
tox21_301588
dtxsid1044560 ,
cas-30007-47-7
dtxcid9024560
B3769
u184i9qbnm ,
unii-u184i9qbnm
5-brom-5-nitro-1,3-dioxan
FT-0620143
5-bromo-5-nitro-1,3-dioxane [inci]
microcide i
SCHEMBL97282
SCHEMBL17347337
Q-200534
XVBRCOKDZVQYAY-UHFFFAOYSA-N
bronidox l
CHEMBL3185787
mfcd00101855
5-bromo-5-nitro-1,3-dioxane, analytical standard
Q4973879
AS-15941
CS-W015032
SY014363
D88989
HY-W014316
PD053603
EN300-7381687
AKOS040744440

Protein Targets (22)

Potency Measurements

ProteinTaxonomyMeasurementAverage (µ)Min (ref.)Avg (ref.)Max (ref.)Bioassay(s)
LuciferasePhotinus pyralis (common eastern firefly)Potency25.18460.007215.758889.3584AID1224835
acetylcholinesteraseHomo sapiens (human)Potency70.97990.002541.796015,848.9004AID1347398
hypoxia-inducible factor 1 alpha subunitHomo sapiens (human)Potency54.94103.189029.884159.4836AID1224846; AID1224894
RAR-related orphan receptor gammaMus musculus (house mouse)Potency23.43750.006038.004119,952.5996AID1159521; AID1159523
GLI family zinc finger 3Homo sapiens (human)Potency43.27710.000714.592883.7951AID1259369; AID1259392
AR proteinHomo sapiens (human)Potency61.22470.000221.22318,912.5098AID1259243; AID1259247; AID743035; AID743036; AID743063
nuclear receptor subfamily 1, group I, member 3Homo sapiens (human)Potency56.09680.001022.650876.6163AID1224838; AID1224893
glucocorticoid receptor [Homo sapiens]Homo sapiens (human)Potency56.56880.000214.376460.0339AID720692; AID720719
retinoic acid nuclear receptor alpha variant 1Homo sapiens (human)Potency54.76600.003041.611522,387.1992AID1159552; AID1159553; AID1159555
retinoid X nuclear receptor alphaHomo sapiens (human)Potency39.15330.000817.505159.3239AID1159527; AID1159531
estrogen-related nuclear receptor alphaHomo sapiens (human)Potency57.76480.001530.607315,848.9004AID1224848; AID1259403
pregnane X nuclear receptorHomo sapiens (human)Potency68.58960.005428.02631,258.9301AID1346982
estrogen nuclear receptor alphaHomo sapiens (human)Potency86.92210.000229.305416,493.5996AID743080; AID743091
peroxisome proliferator activated receptor gammaHomo sapiens (human)Potency48.96620.001019.414170.9645AID743191
vitamin D (1,25- dihydroxyvitamin D3) receptorHomo sapiens (human)Potency48.96620.023723.228263.5986AID743223
cytochrome P450, family 19, subfamily A, polypeptide 1, isoform CRA_aHomo sapiens (human)Potency30.63790.001723.839378.1014AID743083
thyroid stimulating hormone receptorHomo sapiens (human)Potency44.34580.001628.015177.1139AID1224843; AID1224895; AID1259385; AID1259395
activating transcription factor 6Homo sapiens (human)Potency54.94100.143427.612159.8106AID1159516
Histone H2A.xCricetulus griseus (Chinese hamster)Potency44.98780.039147.5451146.8240AID1224845; AID1224896
thyroid hormone receptor beta isoform 2Rattus norvegicus (Norway rat)Potency26.42280.000323.4451159.6830AID743065; AID743066; AID743067
heat shock protein beta-1Homo sapiens (human)Potency54.94100.042027.378961.6448AID743210
nuclear factor erythroid 2-related factor 2 isoform 1Homo sapiens (human)Potency68.58960.000627.21521,122.0200AID743202
[prepared from compound, protein, and bioassay information from National Library of Medicine (NLM), extracted Dec-2023]

Research

Studies (6)

TimeframeStudies, This Drug (%)All Drugs %
pre-19900 (0.00)18.7374
1990's0 (0.00)18.2507
2000's0 (0.00)29.6817
2010's5 (83.33)24.3611
2020's1 (16.67)2.80
[information is prepared from research data collected from National Library of Medicine (NLM), extracted Dec-2023]

Study Types

Publication TypeThis drug (%)All Drugs (%)
Trials0 (0.00%)5.53%
Reviews2 (33.33%)6.00%
Case Studies0 (0.00%)4.05%
Observational0 (0.00%)0.25%
Other4 (66.67%)84.16%
[information is prepared from research data collected from National Library of Medicine (NLM), extracted Dec-2023]
SubstanceDescriptionRelationhip StrengthStudiesTrialsClassesRoles
bronopol[no description available]medium40nitro compound
formaldehyde[no description available]medium40aldehyde;
one-carbon compound		allergen;
carcinogenic agent;
disinfectant;
EC 3.5.1.4 (amidase) inhibitor;
environmental contaminant;
Escherichia coli metabolite;
mouse metabolite;
Saccharomyces cerevisiae metabolite
methenamine[no description available]medium30polyazaalkane;
polycyclic cage;
tetramine		antibacterial drug
1,3-dimethylol-5,5-dimethylhydantoin[no description available]medium20
quaternium-15[no description available]medium30
urea[no description available]medium30isourea;
monocarboxylic acid amide;
one-carbon compound		Daphnia magna metabolite;
Escherichia coli metabolite;
fertilizer;
flour treatment agent;
human metabolite;
mouse metabolite;
Saccharomyces cerevisiae metabolite
sarcosine[no description available]medium10N-alkylglycine zwitterion;
N-alkylglycine;
N-methyl-amino acid;
N-methylglycines		Escherichia coli metabolite;
glycine receptor agonist;
glycine transporter 1 inhibitor;
human metabolite;
mouse metabolite
methanol[no description available]medium30alkyl alcohol;
one-carbon compound;
primary alcohol;
volatile organic compound		amphiprotic solvent;
Escherichia coli metabolite;
fuel;
human metabolite;
mouse metabolite;
Mycoplasma genitalium metabolite
diazolidinylurea[no description available]medium30imidazolidine-2,4-dione
imidazolidinyl urea[no description available]medium30ureasantimicrobial agent
monomethylolglycine[no description available]medium10
hydantoins[no description available]medium30imidazolidine-2,4-dione
propane[no description available]medium10alkane;
gas molecular entity		food propellant
2-nitropropane[no description available]medium10secondary nitroalkanecarcinogenic agent;
hepatotoxic agent;
polar aprotic solvent;
xenobiotic
ConditionIndicatedRelationship StrengthStudiesTrials
Allergic Contact Dermatitis0low30
Dermatitis, Allergic Contact0low30
Dermatitis, Allergic Eczematous0low30
Dermatitis, Contact, Allergic0low30
Sensitivity and Specificity0low10